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ABSTRACT
Background
The relevance of oncology trial results to clinical 
practice depends on whether the trial participants are 
similar to the actual population of patients receiving 
treatment for the malignancy and whether the patients 
are treated similarly in both circumstances. Chemo-
therapy treatments may be more toxic in patients of 
advanced age and poor performance status—patients 
typically excluded from clinical trials.
Methods
In a retrospective chart review that included all non-
trial patients with metastatic colorectal cancer treated 
with irinotecan-based chemotherapy from January 
2004 to September 2006 at our institution, we quan-
tified and subsequently compared the toxicity rates 
of the irinotecan regimens in clinical practice with 
published toxicity rates from corresponding phase iii 
clinical trials. The primary endpoint was the incidence 
of grades 3 and 4 diarrhea.
Results
The study included 203 patients, and the irinotecan 
regimens considered included
●    folfiri [irinotecan, leucovorin, 5-fluorouracil 
(5fu)],
●  ifl (bevacizumab, irinotecan, 5fu, leucovorin),
●  xeliri (capecitabine, 3-weekly irinotecan), and
●  irinotecan monotherapy.
The rates of grades 3 and 4 diarrhea for folfiri, ifl, 
xeliri, and irinotecan monotherapy in clinical practice 
were 10%, 15%, 17%, and 21% as compared with 
10%, 23%, 20%, and 31% respectively in clinical 
trials. When only patients meeting trial performance 
status and age criteria were analyzed, the rates of 
grades 3 and 4 diarrhea by regimen were 11%, 20%, 
19%, and 26% respectively.
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1.  INTRODUCTION
Despite that fact that colorectal cancers tend to occur in 
elderly people, oncology clinical trials have tended to 
exclude elderly patients in favour of patients who are 
younger and who have fewer comorbidities and a better 
performance status 1,2. These population effects—that 
is, the differences between clinical trial and non-trial 
patient populations—have led to a general belief that 
patients enrolled in clinical trials have outcomes that 
are superior compared with those in patients who are 
not included 3–5. Trial effects—such as increased fre-
quency of medical imaging, more frequent follow-up 
visits, and additional attention by clinical trials staff 
during treatment—may lead to additional benefit for 
cancer patients participating in clinical trials.
Despite these assumptions, a systematic review 
has shown that the evidence is insufficient to support 
a claim of improved outcomes for cancer patients who 
participate in clinical trials as compared with patients 
who are not trial participants 6. However, all of the 
studies included in that review focused on efficacy 
endpoints such as overall survival and response to 
treatment; few reported on toxicity.
Irinotecan-based chemotherapy regimens are 
frequently used in the treatment of metastatic colon 
cancer, and they have extended the median survival 
of patients with this disease to 20 months 7. However, 
this survival benefit is not without risk, because iri-
notecan regimens are associated with high rates of 
severe diarrhea 8–10. Although the toxicity rates for 
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folfiri [irinotecan, leucovorin, 5-fluorouracil (5fu)], 
ifl (bevacizumab, irinotecan, 5fu, leucovorin), xeliri 
(capecitabine, 3-weekly irinotecan), and irinotecan 
monotherapy are well documented in publications of 
phase ii and iii clinical trials, we are unaware of any 
studies that document the toxicity of these regimens 
in clinical practice. The objective of the present study 
was to determine whether chemotherapy toxicity 
rates in non-trial patients are similar to those quoted 
in published clinical trials.
2.  PATIENTS AND METHODS
2.1  Study Design
In a retrospective single-institution chart review, the 
incidence of irinotecan-based chemotherapy toxicity 
in the palliative treatment of patients with metastatic 
colorectal cancer was characterized. Toxicity rates 
in clinical practice were compared with those de-
scribed in the largest phase iii clinical trial published 
to date for each regimen. The primary endpoint was 
the incidence of grades 3 and 4 diarrhea. Secondary 
endpoints included the incidence of other grade 3 or 
4 toxicities, hospital admissions for toxicity related to 
chemotherapy, dose reductions or delays because of 
toxicity, discontinuation of chemotherapy secondary 
to toxicity, and chemotherapy-related mortality.
Patients with metastatic colorectal adenocarci-
noma treated with folfiri, ifl, xeliri, or irinotecan 
monotherapy (Table i) between January 1, 2004, and 
September 30, 2006, at the Juravinski Cancer Centre 
(jcc) in Hamilton, Ontario, Canada, were included 
in the study. Patients were excluded if they received 
the chemotherapy of interest in a clinical trial, if their 
pathology was not adenocarcinoma, if they lacked 
documented metastatic sites, and if they received the 
chemotherapy of interest at an institution other than 
the jcc. Charts of the included patients were reviewed 
for demographic, pathology, treatment, and toxicity 
data. Two investigators (VCT, SR) completed the data 
abstraction. Ten percent of the charts were evaluated 
by both investigators to determine inter-observer vari-
ability. Differences in data abstraction were resolved 
by consensus. The remaining 90% of the charts were 
then randomly divided between the two investigators 
for data abstraction.
Toxicities were graded according to the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events, version 3.0. If a toxicity grade was 
not clearly stated in the patient’s chart, the two physi-
cian investigators abstracting the data determined a 
grade based on the information available in each chart 
according to the previously stated criteria. Toxicity 
rates observed in patients treated at the jcc were com-
pared with rates from a clinical trial that delivered the 
identical irinotecan regimen. A separate analysis was 
conducted to compare younger patients (70 years of age 
or younger) with elderly patients (older than 70 years 
of age). A similar comparison was attempted for pa-
tients having a good or fair performance status [Eastern 
Cooperative Oncology Group (ecog) 0–2] with those 
having a poor performance status (ecog 3–4).
For each regimen included in the study, a repre-
sentative comparator was chosen from the literature. 
Where possible, the selected comparator was the larg-
est phase iii trial that used the dose regimen also used 
at our institution. Our main comparator for folfiri 
toxicity was the phase iii clinical trial conducted by 
Colucci et al. 11 The toxicity rates for ifl and irinotecan 
monotherapy were compared with the phase iii trial 
data published by Saltz et al. 9 Unfortunately, phase iii 
toxicity data were not available for xeliri at the time 
of our data analysis. The chosen comparator was 
therefore a phase ii study by Patt et al. 12, which was 
the clinical trial with the largest sample size published 
up to the time of our data analysis.
2.2  Statistical Analysis
Data were recorded and organized using a Microsoft 
Excel spreadsheet (Redmond, WA, U.S.A.). Statisti-
cal analysis was performed using SAS for Windows 
(version 9.1: SAS Institute, Cary, NC, U.S.A.). Inter-
observer variability in data abstraction was assessed 
by calculating percentage agreement and kappa 
statistics. Unadjusted and adjusted analyses were 
both performed. The unadjusted analysis included 
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table i  Chemotherapy regimens
Regimen name Chemotherapy agents Starting dose Schedule per cycle
folfiri Irinotecan 180 mg/m2 Once every 2 weeks
5-Fluorouracil 2400 mg/m2 24-h intravenous infusion With irinotecan
Leucovorin 400 mg/m2 With irinotecan
ifl Irinotecan 80–125 mg/m2 Once weekly for 4–6 weeks
or 180 mg/m2 Once every 2 weeks
5-Fluorouracil 2400 mg/m2 intravenous bolus With irinotecan
Leucovorin 400 mg/m2 With irinotecan
xeliri Irinotecan 250 mg/m2 Once every 3 weeks
Capecitabine 1000 mg/m2 orally Twice daily for 14 days
Irinotecan Irinotecan 80 mg/m2 Once weekly for 4 weeks
monotherapy or 125 mg/m2 Once weekly for 4 weeks15
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all non-trial patients; it describes any benefit derived 
from the combination of population and trial effects. 
The adjusted analysis excluded all non-trial patients 
who did not meet the clinical trial age and perfor-
mance status criteria described in the corresponding 
comparator trials, effectively eliminating population 
effects and focusing on trial effects. Tabulations and 
descriptive statistics were used to analyze the toxicity 
data. Two-sided hypothesis tests for proportions were 
performed using the chi-square test or the Fisher exact 
test when appropriate. A p value less than or equal to 
0.05 was considered significant.
3.  RESULTS
3.1  Patient Characteristics
Figure 1 outlines the patient selection process. 
The study included 203 patients in the unadjusted 
analysis. Of the 203 patients, 137 (67%) met the age 
and performance status criteria of their respective 
comparator clinical trials, and they were used in the 
adjusted analysis.
Table ii outlines the characteristics of the 203 
patients. Fifty patients were over the age of 70 years, 
and 34 of those patients received irinotecan mono-
therapy. An ecog performance status at the time of 
therapy was not recorded for 29% of the patients. Of 
the patients with a clearly described ecog performance 
status, 95% were classified as better than or equal to 
2. At the time of cancer diagnosis, 64% of the patients 
presented with metastatic disease. Upon initiation of 
irinotecan treatment, 64% of the patients had two or 
more metastatic sites. Liver metastases were present 
in 78% of the patients.
For the charts reviewed in duplicate, agreement 
was 100% (κ = 1.0) between the two investigators 
for most of the abstracted data. The exceptions were 
dose reductions and dose delays. Agreement for the 
number of dose reductions was 96% (κ = 0.93), and 
for dose delays, it was 85% (κ = 0.72).
3.2  Rates of Toxicity in the Unadjusted Analysis
Table iii outlines rates of common toxicities encoun-
tered by non-trial patients during treatment with 
irinotecan regimens. Overall, diarrhea was the most 
common adverse event, occurring in 61% of all non-
trial patients. Grades 3 and 4 diarrhea were reported 
in 10% of patients receiving folfiri, in 15% receiving 
ifl, in 17% receiving xeliri, and in 21% receiving 
irinotecan monotherapy. There was no statistically 
significant difference in the rates of grades 3 and 4 
diarrhea observed in non-trial patients treated with 
the four irinotecan regimens as compared with the 
rates observed in patients treated in the comparator 
clinical trials.
Neutropenia was the second most common toxic-
ity, occurring in 54% of the patients. Grades 3 and 4 
neutropenia were reported in 22% of patients receiv-
ing folfiri, in 15% receiving ifl, in 11% receiving 
xeliri, and in 19% receiving irinotecan monotherapy. 
The rate of grades 3 and 4 neutropenia was sig-
nificantly higher in the non-trial patients treated with 
folfiri than in the patients in the study by Colucci et 
al. (p < 0.01). For ifl and irinotecan monotherapy, the 
rates of grades 3 and 4 neutropenia were significantly 
lower in the non-trial patients than in the patients 
in the published comparator studies (p = 0.01 and 
p = 0.02 respectively). A significantly lower rate of 
figure 1  Method of patient selection. jCC = Juravinski Cancer Centre; Capiri = capecitabine–irinotecan.
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grades 3 and 4 vomiting was also observed for non-
trial patients treated with irinotecan monotherapy as 
compared with patients in the clinical trial by Saltz 
et al. (p = 0.05).
Only 9 patients developed febrile neutropenia 
during the study period. Grade 3 febrile neutropenia 
was observed in 5% of patients receiving folfiri, 8% 
receiving ifl, 6% receiving xeliri, and 3% receiving 
irinotecan monotherapy. No reports of grade 4 febrile 
neutropenia were found for the patients included in 
the present study.
3.3  Rates of Toxicity in the Adjusted Analysis
Table iii also shows toxicity rates resulting from 
the adjusted analysis. Grades 3 and 4 diarrhea were 
reported in 11% of patients receiving folfiri, in 20% 
receiving ifl, in 19% receiving xeliri, and in 26% 
receiving irinotecan monotherapy. Again, there was 
no statistically significant difference between the 
rates of grades 3 and 4 diarrhea observed with the 
four irinotecan regimens in the non-trial patients and 
the rates observed in the relevant published clinical 
trial data.
With the exclusion of non-trial patients who 
failed to meet the age and performance criteria in 
the comparator clinical trials, no significant changes 
in the toxicity rates occurred. For folfiri in the non-
trial population, the rates of mucositis and vomiting 
of any grade remained significantly lower and the 
rates of neutropenia of any grade and grades 3 and 
4 neutropenia remained significantly higher than the 
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table ii  Patient characteristics
Characteristic Regimen group
fOlfiri ifl xeliri Irinotecan
(n=102) (n=13) (n=18) monotherapy
(n=70)
Age (years)a
Mean ± standard deviation 59±10 59±11 58±14 68±9
Median 61 54 60 70
Range 29–84 46–83 19–73 44–84
Age > 70 years [n (%)] 10 (10) 2 (15) 4 (22) 34 (49)
Sex [n (%)]
Female 46 (45) 6 (46) 8 (44) 25 (36)
Male 56 (55) 7 (54) 10 (56) 45 (64)
ecog performance status [n (%)]
0 35 (34) 3 (23) 9 (50) 21 (30)
1 26 (26) 2 (15) 6 (33) 15 (21)
2 10 (10) 0 (0) 1 (6) 10 (14)
3 4 (4) 0 (0) 0 (0) 3 (4)
Not available 27 (26) 8 (62) 2 (11) 21 (30)
Site of primary tumour [n (%)]
Colon 62 (61) 7 (54) 14 (78) 39 (56)
Rectum 37 (36) 5 (38) 4 (22) 31 (44)
Not available 3 (3) 0 (0) 0 (0) 0 (0)
Metastatic at diagnosis [n (%)]
Yes 60 (59) 9 (69) 13 (72) 47 (67)
No 42 (41) 4 (31) 5 (28) 23 (33)
Pathology [n (%)]
Well differentiated 7 (7) 1 (8) 0 (0) 2 (3)
Moderately differentiated 73 (72) 9 (69) 15 (83) 45 (64)
Poorly differentiated 20 (20) 0 (0) 1 (6) 17 (24)
Undifferentiated 0 (0) 0 (0) 1 (6) 0 (0)
Not available 2 (2) 3 (23) 1 (6) 6 (9)
Metastatic sites [n (%)]
1 31 (30) 6 (46) 6 (33) 27 (39)
2 40 (39) 4 (31) 7 (39) 28 (40)
>2 31 (30) 3 (23) 5 (28) 15 (21)
Liver involvement [n (%)]
Yes 77 (76) 9 (69) 15 (83) 57 (81)
No 25 (24) 4 (31) 3 (17) 13 (19)
a  At date of first irinotecan treatment.
folfiri = irinotecan, leucovorin, 5-fluorouracil; ifl = bevacizumab, irinotecan, 5-fluorouracil, leucovorin; xeliri = capecitabine, 3-weekly 
irinotecan; ecog = Eastern Cooperative Oncology Group.17
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table iii  Toxicity comparisons by regimen
Regimen and toxicity Unadjusted analysis Adjusted analysis
Trial pts Non-trial pts p Non-trial pts p
[n (%)] [n (%)] Value [n (%)] Value
fOlfiri (n=178)a (n=102) (n=70)
Diarrhea
Any grade 113 (63) 55 (54) 0.07 39 (56) 0.26
Grades 3 and 4 18 (10) 10 (10) 1.00 8 (11) 0.80
Mucositis
Any grade 63 (35) 22 (22) <0.01 16 (23) 0.04
Grades 3 and 4 2 (1) 1 (1) 1.00 1 (1) 1.00
Vomiting
Any grade 128 (71) 26 (26) <0.01 19 (27) <0.01
Grades 3 and 4 8 (4) 3 (3) 1.00 2 (3) 0.93
Neutropenia
Any grade 80 (45) 57 (56) <0.01 43 (61) <0.01
Grades 3 and 4 17 (10) 23 (22) <0.01 16 (23) <0.01
Febrile neutropenia
Any grade na 5 (5) — 4 (6) —
Grades 3 and 4 na 5 (5) — 4 (6) —
ifl (n=225)b (n=13) (n=5)
Diarrhea
Any grade na 8 (62) — 4 (80) —
Grades 3 and 4 na (23) 2 (15) 0.81 1 (20) 1.00
Mucositis
Any grade na 3 (23) — 1 (20) —
Grades 3 and 4 na (2) 0 (0) 1.00 0 (0) 1.00
Vomiting
Any grade na 2 (15) — 1 (20) —
Grades 3 and 4 na (10) 0 (0) 0.53 0 (0) 1.00
Neutropenia
Any grade na 9 (69) — 4 (80) —
Grades 3 and 4 na (54) 2 (15) 0.01 0 (0) 0.04
Febrile neutropenia
Any grade na (7) 1 (8) 1.00 1 (20) 0.61
Grades 3 and 4 na 1 (8) — 1 (20) —
xeliri (n=51)c (n=18) (n=16)
Diarrhea
Any grade na (78) 14 (78) 1.00 12 (75) 0.96
Grades 3 and 4 na (20) 3 (17) 1.00 3 (19) 1.00
Mucositis
Any grade na 1 (6) — 1 (6) —
Grades 3 and 4 na 0 (0) — 0 (0) —
Vomiting
Any grade na (61) 6 (33) 0.03 5 (31) 0.03
Grades 3 and 4 na (17) 0 (0) 0.07 0 (0) 0.10
Neutropenia
Any grade na (37) 6 (33) 0.98 5 (31) 0.85
Grades 3 and 4 na (25) 2 (11) 0.27 2 (12) 0.39
Febrile neutropenia
Any grade na 1 (6) — 1 (6) —
Grades 3 and 4 na 1 (6) — 1 (6) —
Irinotecan monotherapy (n=223)b (n=70) (n=46)
Diarrhea
Any grade na 46 (66) — 31 (67) —
Grades 3 and 4 na (31) 15 (21) 0.10 12 (26) 0.58
Mucositis
Any grade na 5 (7) — 3 (6) —
Grades 3 and 4 na (2) 1 (1) 1.00 1 (2) 1.00
Vomiting
Any grade na 19 (27) — 12 (26) —
Grades 3 and 4 na (12) 3 (4) 0.05 1 (2) 0.04
Neutropenia
Any grade na 38 (54) — 29 (63) —
Grades 3 and 4 na (31) 13 (19) 0.02 9 (19) 0.12
Febrile neutropenia
Any grade na (6) 2 (3) 0.44 2 (4) 0.94
Grades 3 and 4 na 2 (3) — 2 (4) —
a  Colucci et al. 11
b  Saltz et al. 9
c  Patt et al. 13
na = not available from published clinical trial article.
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rates reported in the clinical trial results. The rates 
of grades 3 and 4 neutropenia with ifl, vomiting of 
any grade with xeliri, and grades 3 and 4 vomiting 
with irinotecan monotherapy remained significantly 
lower in non-trial patients. The lower rate of grades 3 
and 4 neutropenia for non-trial patients treated with 
irinotecan monotherapy was no longer statistically 
significant in the adjusted analysis (p = 0.12).
3.4  Consequences of Chemotherapy Toxicity
Table iv shows the clinical consequences of toxicities 
from treatment with the four irinotecan regimens. 
Only selected consequences of chemotherapy toxicity 
were reported in the publications of the comparator 
trials, and therefore a systematic comparison was not 
possible. With the information provided by the com-
parator clinical trial publications, we found several 
statistically significant differences. In the unadjusted 
analysis, the rate of premature discontinuation of 
ifl treatment secondary to toxicity was 31% in the 
non-trial patients as compared with 8% in the trial 
patients (p = 0.02). For non-trial patients treated with 
irinotecan monotherapy, the rate of premature dis-
continuation of irinotecan chemotherapy in the non-
trial patients secondary to toxicity was in the range 
24%–26%, which was significantly higher than the 
6% quoted in the comparator trial (p < 0.01). A similar 
trend was observed for deaths related to irinotecan 
monotherapy toxicity, which showed a death rate in 
non-trial patients of 4%–7% as compared with 1% 
in the comparator trial (p = 0.03).
Overall, there was no clear trend toward an 
increase or decrease in the rates of toxicity conse-
quences when comparing the unadjusted and adjusted 
analyses. The highest rates of hospital admission, 
dose delays, premature discontinuation of irinotecan 
chemotherapy, and deaths related to irinotecan che-
motherapy were seen with ifl as compared with the 
other three irinotecan regimens. The rate of overall 
death while on irinotecan chemotherapy was also 
highest in patients treated with ifl (15%).
3.5  Comparison of Toxicity According to Age
The analysis of irinotecan toxicity in younger patients 
as compared with elderly patients (older than 70 years) 
showed no significant differences in the rates of diar-
rhea, mucositis, vomiting, neutropenia, and febrile 
neutropenia between the two groups. However, admis-
sions for chemotherapy side effects were significantly 
more frequent in the elderly patients as compared with 
the younger patients (26% vs. 10%, p = 0.02). The 
incidence of premature discontinuation of irinotecan 
chemotherapy was also significantly higher in the 
elderly patients (30% vs. 14%, p = 0.02).
3.6  Comparison of Toxicity According to  
Performance Status
In 145 patients, a performance status was clearly 
defined; data regarding performance status were un-
available in the remaining patient records. Irinotecan 
toxicity for patients with a good or fair performance 
status (ecog 0–2) was compared with that for patients 
with a poor performance status (ecog 3–4). However, 
only 7 non-trial patients had a poor performance sta-
tus, and the sample size was therefore too small for 
any meaningful comparisons to be made.
4.  DISCUSSION
As compared with patients in published clinical trials, 
non-trial patients with metastatic colorectal cancer do 
not appear to experience increased rates of toxicity 
when treated with irinotecan chemotherapy. The only 
exception is a higher rate of grades 3 and 4 neutropenia 
in non-trial patients treated with folfiri: 22% versus 
10% in a comparator study (p < 0.01). However, that 
finding might be explained by the abnormally low rate 
of grades 3 and 4 neutropenia reported in the study 
by Colucci et al. The combined incidence of grades 3 
and 4 neutropenia in phase iii clinical trials of folfiri 
has been noted to be 24%, which is nearly equivalent 
to the rate in our study population 7.
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table iv  Consequences of chemotherapy toxicity
Consequence Patients [n (%)]
of toxicity fOlfiri ifl xeliri Irinotecan  
monotherapy
Adjusted
  No  Yes
Adjusted
  No  Yes
Adjusted
  No  Yes
Adjusted
  No  Yes
(n=102) (n=70) (n=13) (n=5) (n=18) (n=16) (n=70) (n=46)
One or more admissions for irinotecan chemo-
therapy side effects
11 (11) 8 (11) 3 (23) 1 (20) 1 (6) 1 (6) 13 (19) 10 (22)
Dose delays secondary to irinotecan toxicity 43 (42) 31 (44) 9 (69) 4 (80) 6 (33) 6 (38) 30 (43) 18 (39)
Dose reductions secondary to irinotecan toxicity 40 (39) 29 (41) 3 (23) 1 (20) 8 (44) 7 (44) 35 (50) 23 (50)
Premature discontinuation of irinotecan chemo-
therapy secondary to toxicity
12 (12) 9 (13) 4 (31) 2 (40) 3 (17) 2 (12) 17 (24) 12 (26)
Deaths while still on irinotecan chemotherapy 9 (9) 4 (6) 2 (15) 0 (0) 0 (0) 0 (0) 6 (9) 3 (7)
Deaths related to irinotecan chemotherapy toxicity 0 (0) 0 (0) 1 (8) 0 (0) 0 (0) 0 (0) 3 (4) 3 (7)19
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The rates of several toxicities were actually sig-
nificantly lower in our non-trial patients, as in the 
case of vomiting of any grade in the folfiri group and 
of grades 3 and 4 neutropenia in the ifl group. One 
possible explanation for these differences is that the 
documentation of toxicities is poor in the chart notes 
of non-trial patients as compared with patients on 
clinical trials. Some of the significantly lower toxicity 
rates may also be a result of chance, because multiple 
comparisons were made and sample sizes were small 
in some groups—particularly for ifl, which is now 
seldom used in clinical practice, and for xeliri, which 
is a relatively new regimen.
Peppercorn et al. published a systematic review 
of studies comparing outcomes between trial and 
non-trial cancer patients 6. In unadjusted analyses, 
13 of 21 studies (62%) showed some evidence of 
improved outcomes in trial patients. In adjusted 
analyses, where confounding factors were accounted 
for, 11 of 17 studies (65%) showed better outcomes in 
the trial patients. However, the overall conclusion by 
those authors was that the evidence is insufficient to 
prove that enrolment in cancer clinical trials leads to 
improved outcomes. It should be noted that nearly all 
the outcomes examined by studies in the systematic 
review were efficacy endpoints such as survival and 
response rate. Because treatment decisions are based 
both on efficacy and on toxicity of a chemotherapy 
regimen, our study provides oncologists with im-
portant evidence supporting the generalizability of 
clinical trial toxicity rates to non-trial patients.
Specific age and performance status criteria are 
prominent in the inclusion criteria for many clinical 
trials. These factors are important in the analysis of 
irinotecan toxicity, because age older than 70 years 
and ecog performance status less than 2 have gen-
erally been regarded as risk factors for developing 
irinotecan toxicity. As a result, several large clinical 
trials of irinotecan regimens have used an initial dose 
reduction for all elderly patients 13–15.
With respect to age, it is well documented that 
patients enrolled in clinical trials tend to be younger 
than non-trial patients and also younger than the over-
all population of patients with the malignancy 1,2,4. 
Differences in age are theoretically important, be-
cause medications have different pharmacokinetics 
in elderly people, who tend to have decreased renal 
and liver function, lower total body water, and higher 
amounts of adipose tissue 16,17. In addition, elderly 
people are generally perceived as having multiple 
comorbid conditions, limited socioeconomic support, 
and reduced cognition, which may limit the potential 
benefit from systemic cancer therapy 17. Despite these 
theoretic risks, we did not find any significant increase 
in grades 3 and 4 toxicity rates in non-trial patients 
older than 70 years. Our findings are supported by 
several studies that have found irinotecan regimens 
to be well tolerated in fit elderly patients 18–21. Thus, 
the current general consensus is that elderly patients 
fit enough to enrol in clinical trials can be treated with 
chemotherapy. Frail elderly patients are more likely 
to suffer adverse outcomes when faced with stressors, 
and they should not receive systemic chemotherapy. 
Unfortunately, because of the underrepresentation of 
elderly patients in cancer clinical trials, the evidence 
is insufficient to support or oppose the use of chemo-
therapy in the preponderance of elderly patients who 
have an intermediate performance status 22.
It has been well established that patients with a 
poor performance status have a worse prognosis and 
that they may have reduced response to chemotherapy 
treatment and increased rates of toxicity 23. As a re-
sult, these patients are almost always excluded from 
clinical trials. Of patients in the present study with 
a clearly defined performance status, the proportion 
that were ecog 0 or 1 was 82% among non-trial fol-
firi patients as compared with 98% among patients 
in the Colucci et al. comparator study. Also, of our 
non-trial folfiri patients with a clearly determined 
performance status, 5% had an ecog performance 
status of 3 and would have been ineligible for the 
comparator trial. That ineligible proportion may have 
been even greater, given that performance status was 
not documented for 26% of the folfiri patients.
The present study has several limitations. Be-
cause of the retrospective design, we were unable 
to mandate rigorous documentation of toxicities for 
the non-trial patients, possibly leading to underesti-
mation of toxicity rates. Although we attempted to 
adjust the analysis for the inclusion criteria of the 
clinical trials, only age and performance status were 
accounted for. The four comparator trials used nu-
merous exclusion criteria that varied between them, 
preventing a practical accounting for those criteria 
in the non-trial population.
5.  CONCLUSIONS
The folfiri and irinotecan monotherapy regimens do 
not appear to cause higher rates of toxicity in non-
trial patients than in patients treated in clinical trials. 
However, we advise caution in generalizing clinical 
trial toxicity data to patients who fail to meet trial 
inclusion criteria.
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